Advertisement

Topics

A review of dupilumab in the treatment of atopic diseases.

07:00 EST 20th February 2019 | BioPortfolio

Summary of "A review of dupilumab in the treatment of atopic diseases."

Dupilumab is a fully human monoclonal IgG4 antibody directed against the alpha subunit of the IL-4 receptor and prevents the signaling of IL-4 and IL-13, two type 2 cytokines known to be important drivers of atopic diseases. In March of 2017, the United States Food and Drug Administration (FDA) approved dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults that is uncontrolled with topical medications, becoming the first biologic agent approved to treat this chronic skin condition. In October of 2018, Dupilumab received approval by the FDA as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years or older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. This review summarizes the characteristics of dupilumab and the clinical research that has been published to date, including treatment efficacy and adverse events.

Affiliation

Journal Details

This article was published in the following journal.

Name: Human vaccines & immunotherapeutics
ISSN: 2164-554X
Pages:

Links

DeepDyve research library

PubMed Articles [33762 Associated PubMed Articles listed on BioPortfolio]

Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real life practice.

Dupilumab has demonstrated efficacy in atopic dermatitis (AD) , asthma , perennial allergic rhinitis and chronic sinusitis . The objectives of this prospective observational, single-centre study were ...

Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients.

Dupilumab is an IL-4Rα monoclonal antibody inhibiting signaling of IL-4/IL-13, key drivers of Type 2-driven inflammation, as demonstrated by its efficacy in atopic/allergic diseases.

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.

Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti-interleukin (IL)-4Rα antibody inhibiting IL-4 and IL-13, compared to patients trea...

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.

Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.

Hair regrowth and dissemination of molluscum contagiosum: two unexpected effects with dupilumab.

Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that was approved by the US Food and Drug Administration in April 2017 for the treatment of adult patients with moderate-to-severe atopic d...

Clinical Trials [5472 Associated Clinical Trials listed on BioPortfolio]

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

This is a single-arm, open-label study, which will examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis lesions.

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis...

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis...

Medical and Biotech [MESH] Definitions

Review of the medical necessity of hospital or other health facility admissions, upon or within a short time following an admission, and periodic review of services provided during the course of treatment.

Antigens from the house dust mites (DERMATOPHAGOIDES), mainly D. farinae and D. pteronyssinus. They are proteins, found in mite feces or mite extracts, that can cause ASTHMA and other allergic diseases such as perennial rhinitis (RHINITIS, ALLERGIC, PERENNIAL) and atopic dermatitis (DERMATITIS, ATOPIC). More than 11 groups of Dermatophagoides ALLERGENS have been defined. Group I allergens, such as Der f I and Der p I from the above two species, are among the strongest mite immunogens in humans.

Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for Medicaid programs beginning in 1993.

Organizations representing designated geographic areas which have contracts under the PRO program to review the medical necessity, appropriateness, quality, and cost-effectiveness of care received by Medicare beneficiaries. Peer Review Improvement Act, PL 97-248, 1982.

A disseminated vesicular-pustular eruption caused by the herpes simplex virus (HERPESVIRUS HOMINIS), the VACCINIA VIRUS, or Varicella zoster (HERPESVIRUS 3, HUMAN). It is usually superimposed on a preexisting, inactive or active, atopic dermatitis (DERMATITIS, ATOPIC).

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Searches Linking to this Article